AUTL Autolus Therapeutics plc
Price (delayed)
$3.95
Market cap
$1.05B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.17
Enterprise value
$632.8M
autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a
Highlights
Autolus Therapeutics's quick ratio has surged by 130% YoY
The company's gross profit rose by 40% YoY
Autolus Therapeutics's equity has surged by 130% YoY but it has decreased by 9% QoQ
AUTL's debt has soared by 55% year-on-year and by 3.2% since the previous quarter
Autolus Therapeutics's net income has shrunk by 51% YoY and by 6% QoQ
Key stats
What are the main financial stats of AUTL
Market
Valuations
Earnings
Shares outstanding
266.09M
Market cap
$1.05B
Enterprise value
$632.8M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.99
Price to sales (P/S)
100.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60.28
Revenue
$10.5M
EBIT
-$161.93M
EBITDA
-$148.73M
Free cash flow
-$160.97M
Per share
Balance sheet
Liquidity
EPS
-$1.17
Free cash flow per share
-$0.61
Book value per share
$1.98
Revenue per share
$0.04
TBVPS
$3.21
Total assets
$853.62M
Total liabilities
$325.78M
Debt
$288.68M
Equity
$527.84M
Working capital
$717.7M
Debt to equity
0.55
Current ratio
18.55
Quick ratio
17.28
Net debt/EBITDA
2.81
Margins
Efficiency
Dividend
EBITDA margin
-1,416.9%
Gross margin
100%
Net margin
-2,229%
Operating margin
-1,775.7%
Return on assets
-36.9%
Return on equity
-66.8%
Return on invested capital
-46.6%
Return on capital employed
-19.9%
Return on sales
-1,542.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AUTL stock price
How has the Autolus Therapeutics stock price performed over time
Intraday
-3.42%
1 week
-11.04%
1 month
7.34%
1 year
33.45%
YTD
-38.66%
QTD
13.51%
Financial performance
How have Autolus Therapeutics's revenue and profit performed over time
Revenue
$10.5M
Gross profit
$10.5M
Operating income
-$186.4M
Net income
-$233.98M
Gross margin
100%
Net margin
-2,229%
Autolus Therapeutics's net income has shrunk by 51% YoY and by 6% QoQ
The company's gross profit rose by 40% YoY
Autolus Therapeutics's revenue has increased by 40% YoY
Autolus Therapeutics's operating income has decreased by 34% YoY and by 8% QoQ
Growth
What is Autolus Therapeutics's growth rate over time
Valuation
What is Autolus Therapeutics stock price valuation
P/E
N/A
P/B
1.99
P/S
100.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60.28
The EPS has grown by 3.3% since the previous quarter
Autolus Therapeutics's equity has surged by 130% YoY but it has decreased by 9% QoQ
AUTL's price to book (P/B) is 51% lower than its last 4 quarters average of 4.2 and 6% lower than its 5-year quarterly average of 2.2
AUTL's price to sales (P/S) is 57% lower than its last 4 quarters average of 239.1 and 53% lower than its 5-year quarterly average of 221.3
Autolus Therapeutics's revenue has increased by 40% YoY
Efficiency
How efficient is Autolus Therapeutics business performance
Autolus Therapeutics's ROIC has increased by 25% YoY and by 2.9% from the previous quarter
The return on equity has grown by 17% since the previous quarter but it has declined by 2.9% year-on-year
Autolus Therapeutics's return on assets has increased by 11% QoQ
The return on sales has grown by 9% year-on-year but it has declined by 4.9% since the previous quarter
Dividends
What is AUTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AUTL.
Financial health
How did Autolus Therapeutics financials performed over time
The company's total assets is 162% higher than its total liabilities
Autolus Therapeutics's quick ratio has surged by 130% YoY
AUTL's current ratio has surged by 114% year-on-year
AUTL's debt is 45% smaller than its equity
Autolus Therapeutics's equity has surged by 130% YoY but it has decreased by 9% QoQ
AUTL's debt has soared by 55% year-on-year and by 3.2% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.